查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954609

全球人類抗凝血酶市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Human Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 請詢問到貨日

價格

人類抗凝血酶市場成長驅動因子

2025年全球人抗凝血酶市場規模為3.8132億美元，預計將從2026年的3.9634億美元成長至2034年的5.6636億美元，在預測期（2026-2034年）內年複合成長率（CAGR）為4.56%。2025年，歐洲憑藉強大的血漿分離基礎設施和主要生產商的存在，以43.17%的市場佔有率佔據主導地位。

人類抗凝血酶是一種血漿來源的糖蛋白，它透過滅活凝血酶和其他絲氨酸蛋白酶，在調節血液凝固中發揮著非常重要的作用。它廣泛用於預防異常血液凝固，尤其適用於遺傳性抗凝血酶缺乏症患者以及高風險手術和重症監護環境。

市場概覽

人類抗凝血酶濃縮物對於凝血障礙的治療非常重要，尤其對接受複雜手術的患者以及血栓形成和瀰漫性血管內凝血（DIC）患者而言意義重大。心血管疾病盛行率的上升、器官移植手術數量的增加以及體外膜氧合（ECMO）的廣泛應用是市場成長的主要驅動因素。

該市場的主要參與者包括CSL、Octapharma AG、Grifols、S.A.、Kedrion S.p.A.、Takeda Pharmaceutical Company Limited。這些公司在血漿衍生藥物領域擁有強大的影響力，推動了整體市場成長。

市場動態

市場驅動因素

治療應用的日益廣泛

主要的成長驅動因素是人類抗凝血酶治療應用的不斷擴展。需要心臟手術、器官移植和抗凝血治療的危重患者數量不斷增加，推動了市場需求。根據2024年6月發表於Annals of Thoracic Surgery Short Reports的一篇文章 ，美國每年平均每10萬人接受271.5例心臟手術。

遺傳性抗凝血酶缺乏症影響全球約0.02%至0.05%的人口，因此需要終身替代療法。外科醫生和重症監護室（ICU）醫生越來越依賴速效抗凝血酶製劑，預計該市場將從2026年的3.9634億美元成長到2034年的5.6636億美元。

市場限制因子

安全性問題和副作用

儘管血漿來源的抗凝血酶濃縮物已廣泛用於治療，但仍存在一定的風險。這些不良反應包括過敏反應、過敏性休克、出血併發症和血栓栓塞。儘管採取了嚴格的安全措施，但仍存在傳播未知病原體的風險，儘管這種風險很小。在嚴重敗血症病例中，高劑量抗凝血酶 III 和肝素合併使用可能會增加出血風險。這些因素限制了其在某些臨床場景中的應用。

市場機會

聯合療法的發展

聯合療法研究的進展創造新的機會。研究表明，抗凝血酶和肝素的聯合使用具有協同抗凝血作用。醫療專業人員積極探索此類聯合療法增強療效的潛力。將適應症擴展到遺傳性缺陷以外的領域，尤其是在敗血症和瀰漫性血管內凝血（DIC）的治療方面，預計將帶來長期的成長機會。

市場挑戰

複雜的監理與償付框架

血漿衍生產品的嚴格監管要求延緩了產品審批和商業化的進程。此外，各國償付政策的差異限制了產品的可及性，尤其是在中低收入國家。儘管臨床需求旺盛，但這些挑戰可能會抑制市場滲透。

市場趨勢

臨床應用範圍的擴大

抗凝血酶的應用範圍日益廣泛，已不再局限於治療遺傳性凝血功能障礙。在日本，抗凝血酶濃縮物已被納入敗血症合併瀰漫性血管內凝血（DIC）患者的抗凝血治療標準方案。日本醫療體系核准的每日劑量為1500國際單位。這種臨床應用範圍的擴大代表著一個重要的市場趨勢。

市場區隔分析

依應用領域劃分

市場依應用領域分為治療應用與研究/診斷應用。

  • 2024年，治療應用佔據市場主導地位，並因臨床需求旺盛而持續保持領先地位。抗凝血酶替代療法廣泛用於治療肝素抵抗，2024年12月，美國血液學會推薦抗凝血酶替代療法作為此類病例的首選治療方案。
  • 另一方面，由於產品供應有限，研究/診斷應用領域的市場佔有率較小。

依劑型劃分

市面上依劑型分為凍乾粉劑和液體劑。

  • 2024年，凍乾粉劑因其穩定性較佳且易於儲存，佔據了主要市場佔有率。 THROMBATE III（Griffols）和Thrombotrol VF（CSL）等產品均以冷凍乾燥粉末形式供應。
  • 由於市售產品數量有限，液體劑型市場佔有率較小。

依最終使用者劃分

市場包括醫院和診所、製藥和生物技術公司以及研究機構。

  • 2024年，由於外科手術和重症監護環境中使用量的增加，醫院和診所佔據了最大的市場佔有率。
  • 由於研究應用範圍的擴大，製藥和生物技術公司預計將穩定成長。

區域展望

歐洲

到2025年，歐洲以1.6462億美元的市場規模和43.17%的市場佔有率引領市場。其成長得益於強大的血漿生產基礎設施、政府支持措施（例如 "法國2030" 計畫）以及LFB和Griffols等領先企業的存在。

亞太地區

由於先天性缺陷病例數量的增加以及戰略合作夥伴關係的建立，預計亞太地區將實現最快的成長。例如，2019年，SK Pharma 與 BioPharma Indonesia 合作開展了一項血漿生產計畫。

北美

由於監管障礙限制了產品審批，北美市場佔有率相對較小。

世界其他地區

預計拉丁美洲以及中東和非洲地區將實現溫和成長，這主要得益於醫療保健可近性的提高。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 關鍵因素注意事項

  • 主要心血管疾病盛行率：依主要國家劃分
  • 監理狀況：依主要國家劃分
  • 關鍵產業趨勢（併購、業務合作、核准、上市等）

第5章 全球人類抗凝血酶市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依應用領域劃分
    • 治療應用
    • 研究與診斷
  • 市場分析、洞察與預測：依劑型劃分
    • 冷凍乾燥粉劑
    • 液體製劑
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 製藥公司與生技產業
    • 研究機構
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區（ROW）

第6章 北美人類抗凝血酶市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲人類抗凝血酶市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家國家/地區

第8章 亞太地區人類抗凝血酶市場分析：洞察與預測（2021-2034）

  • 國家細分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 東南亞
    • 其他亞太地區

第9章 其他地區（ROW）人類抗凝血酶市場分析：洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • CSL
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Grifols, S.A.
    • Medix Biochemica
    • Kedrion S.p.A.
    • Scripps Laboratories
Product Code: FBI113611

Growth Factors of human antithrombin Market

The global human antithrombin market was valued at USD 381.32 million in 2025 and is projected to grow from USD 396.34 million in 2026 to USD 566.36 million by 2034, registering a CAGR of 4.56% during the forecast period (2026-2034). In 2025, Europe dominated the market with a 43.17% share, supported by strong plasma fractionation infrastructure and the presence of leading manufacturers.

Human antithrombin is a plasma-derived glycoprotein that plays a vital role in regulating blood coagulation by inactivating thrombin and other serine proteases. It is widely used for preventing abnormal blood clotting, particularly in patients with hereditary antithrombin deficiency and in high-risk surgical or critical care settings.

Market Overview

Human antithrombin concentrates are essential in managing coagulation disorders, especially in patients undergoing complex surgical procedures or those suffering from thrombophilia and disseminated intravascular coagulation (DIC). The growing prevalence of cardiovascular diseases, increasing organ transplant procedures, and rising use of extracorporeal membrane oxygenation (ECMO) are key factors contributing to market expansion.

Major companies operating in this market include CSL, Octapharma AG, Grifols, S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited. Their strong presence in plasma-derived medicinal products strengthens overall market growth.

Market Dynamics

Market Drivers

Increasing Usage for Therapeutic Applications

The primary growth driver is the expanding therapeutic application of human antithrombin. The rising number of cardiac surgeries, organ transplants, and critically ill patients requiring anticoagulant therapy is increasing demand. According to a June 2024 article published in Annals of Thoracic Surgery Short Reports, the annual average cardiac surgery volume in the U.S. reached 271.5 procedures per 100,000 population.

Hereditary antithrombin deficiency affects approximately 0.02% to 0.05% of the global population, creating sustained demand for lifelong supplementation therapy. Surgeons and ICU physicians increasingly depend on fast-acting antithrombin formulations, supporting market growth from USD 396.34 million in 2026 to USD 566.36 million by 2034.

Market Restraints

Safety Concerns and Side Effects

Despite widespread therapeutic use, plasma-derived antithrombin concentrates carry certain risks. These include allergic reactions, anaphylaxis, bleeding complications, and thromboembolic events. There is also a minimal risk of transmission of unknown infectious agents, despite rigorous safety measures. In cases of severe sepsis, high-dose antithrombin III combined with heparin may increase hemorrhage risk. These factors limit adoption in certain clinical scenarios.

Market Opportunities

Expansion into Combination Therapies

Growing research on combination therapies is creating new opportunities. Studies indicate that combining antithrombin with heparin produces synergistic anticoagulant effects. Healthcare professionals are increasingly exploring such combinations to enhance therapeutic outcomes. The expansion of applications beyond hereditary deficiency, particularly in sepsis and DIC management, is expected to provide long-term growth opportunities.

Market Challenges

Complex Regulatory and Reimbursement Frameworks

Strict regulatory requirements for plasma-derived products slow product approvals and commercialization timelines. Additionally, reimbursement disparities across countries limit accessibility, especially in low- and middle-income nations. These challenges can restrain market penetration despite clinical demand.

Market Trends

Expanding Clinical Applications

Antithrombin is increasingly used beyond hereditary deficiency treatment. In Japan, anticoagulation therapy for septic patients with DIC includes antithrombin concentrate as part of standard care. A dose of 1,500 IU/day has been approved within the Japanese healthcare system. Such expanded clinical applications represent a notable market trend.

Segmentation Analysis

By Application

The market is segmented into therapeutic and research & diagnostic applications.

  • The therapeutic segment dominated the market in 2024 and continues to lead due to high clinical demand. Antithrombin supplementation is widely used to manage heparin resistance. In December 2024, the American Society of Hematology highlighted antithrombin supplementation as a preferred treatment in such cases.
  • The research & diagnostic segment holds a smaller share due to limited product availability.

By Dosage Form

The market is categorized into lyophilized powder and liquid formulations.

  • Lyophilized powder held the dominant share in 2024, owing to enhanced stability and ease of storage. Products such as THROMBATE III (Grifols) and Thrombotrol VF (CSL) are available in this form.
  • The liquid segment accounts for a smaller share due to limited commercial availability.

By End User

The market includes hospitals & clinics, pharmaceutical & biotechnology companies, and research institutes.

  • Hospitals & clinics held the largest share in 2024 due to increased usage in surgical and critical care settings.
  • The pharmaceutical and biotechnology segment is expected to grow steadily due to expanding research applications.

Regional Outlook

Europe

Europe led the market with a value of USD 164.62 million in 2025 and a 43.17% market share. Growth is driven by strong plasma manufacturing infrastructure, supportive government initiatives such as "France 2030," and the presence of major players like LFB and Grifols.

Asia Pacific

Asia Pacific is projected to witness the fastest growth due to rising congenital deficiency cases and strategic collaborations. For example, in 2019, SK Pharma partnered with BioPharma Indonesia for plasma production initiatives.

North America

North America holds a comparatively smaller share due to regulatory hurdles limiting product approvals.

Rest of the World

Latin America and the Middle East & Africa are experiencing gradual growth, supported by improving healthcare access.

Competitive Landscape

The market is semi-consolidated, with leading players including CSL, Grifols, Kedrion, and Octapharma AG. These companies maintain strong global distribution networks and plasma-derived product portfolios. Strategic collaborations, facility expansions, and clinical trials are shaping the competitive environment.

Conclusion

The global human antithrombin market is expected to grow steadily from USD 381.32 million in 2025 to USD 566.36 million by 2034, driven by rising surgical procedures, increasing cases of hereditary deficiency, and expanding therapeutic applications. While safety concerns and regulatory complexities present challenges, ongoing research, combination therapies, and strong European leadership are likely to sustain long-term market expansion. As healthcare systems continue to prioritize advanced anticoagulation management, human antithrombin will remain a critical component in treating complex coagulation disorders worldwide.

Segmentation By Application

  • Therapeutic
  • Research & Diagnostic

By Dosage Form

  • Lyophilized Powder
  • Liquid

By End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region

  • North America (By Application, Dosage Form, End User, and Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
  • 4.2. Regolatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research & Diagnostic
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Lyophilized Powder
    • 5.2.2. Liquid
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research & Diagnostic
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Lyophilized Powder
    • 6.2.2. Liquid
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research & Diagnostic
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Lyophilized Powder
    • 7.2.2. Liquid
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. UK
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research & Diagnostic
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Lyophilized Powder
    • 8.2.2. Liquid
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Southeast Asia
    • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research & Diagnostic
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Lyophilized Powder
    • 9.2.2. Liquid
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. CSL
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. Financials (Based on Availability)
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. SWOT,Etc.
    • 10.2.2. Octapharma AG
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. Financials (Based on Availability)
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. SWOT,Etc.
    • 10.2.3. Takeda Pharmaceutical Company Limited
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. Financials (Based on Availability)
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. SWOT,Etc.
    • 10.2.4. Grifols, S.A.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. Financials (Based on Availability)
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. SWOT,Etc.
    • 10.2.5. Medix Biochemica
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. Financials (Based on Availability)
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. SWOT,Etc.
    • 10.2.6. Kedrion S.p.A.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. Financials (Based on Availability)
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. SWOT,Etc.
    • 10.2.7. Scripps Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. Financials (Based on Availability)
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 2: Global Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 3: Global Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 4: Global Human Antithrombin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 6: North America Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 7: North America Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 8: North America Human Antithrombin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 10: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 11: Europe Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Europe Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 14: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 15: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 18: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 19: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034

List of Figures

  • Figure 1: Global Human Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Human Antithrombin Market Value Share (%), by Application, 2025 & 2034
  • Figure 3: Global Human Antithrombin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Human Antithrombin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Human Antithrombin Market Value (USD million), by Region, 2025 & 2034
  • Figure 6: North America Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 7: North America Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 8: North America Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 9: North America Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 10: North America Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 11: North America Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 12: North America Human Antithrombin Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Human Antithrombin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 15: Europe Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 16: Europe Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 17: Europe Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 18: Europe Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 20: Europe Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 21: Europe Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Europe Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Asia Pacific Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 24: Asia Pacific Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 25: Asia Pacific Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 26: Asia Pacific Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 27: Asia Pacific Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 28: Asia Pacific Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 29: Asia Pacific Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Rest of the World Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Rest of the World Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 33: Rest of the World Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 34: Rest of the World Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 35: Rest of the World Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 36: Rest of the World Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 37: Global Human Antithrombin Market Share (%), By Company, 2025